|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM302455825 |
| 003 |
DE-627 |
| 005 |
20231227130124.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.108265
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1224.xml
|
| 035 |
|
|
|a (DE-627)NLM302455825
|
| 035 |
|
|
|a (NLM)31639447
|
| 035 |
|
|
|a (PII)S1521-6616(19)30422-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Flessa, Christina-Maria
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Independent association of low IFNλ1 gene expression and type I IFN score/IFNλ1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.05.2020
|
| 500 |
|
|
|a Date Revised 13.12.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2019. Published by Elsevier Inc.
|
| 520 |
|
|
|a Recent data suggest an important role of type I interferons (IFN) in antiphospholipid syndrome (APS). Here we aimed to evaluate the interplay of type I and type III (or IFNλs) IFNs in APS and potential clinical and serological associations. Our findings suggest that patients with primary APS (PAPS) and systemic lupus erythematosus (SLE)/APS displayed increased type I IFN scores but decreased IFNλ1 gene expression levels compared to healthy individuals, as assessed with real-time qPCR analysis in isolated peripheral blood mononuclear cells (PBMCs). Type I IFN score/IFNλ1 ratio was remarkably higher in patients with PAPS and SLE/APS as well as in SLE patients with or without antiphospholipid antibodies (aPL) vs controls. In conclusion, our results reveal an association between low IFNλ1 expression and obstetric APS. Moreover, the type I IFN score/IFNλ1 ratio seems to be a potential marker of high risk APS given its associations with triple aPL positivity
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Antiphospholipid syndrome
|
| 650 |
|
4 |
|a IFNλ1 gene expression
|
| 650 |
|
4 |
|a Obstetric manifestations
|
| 650 |
|
4 |
|a Systemic lupus erythematosus
|
| 650 |
|
4 |
|a Triple antiphospholipid antibody positivity
|
| 650 |
|
4 |
|a Type I IFN score
|
| 650 |
|
7 |
|a Antibodies, Antiphospholipid
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a interferon-lambda, human
|2 NLM
|
| 650 |
|
7 |
|a Interferon Type I
|2 NLM
|
| 650 |
|
7 |
|a Interleukins
|2 NLM
|
| 650 |
|
7 |
|a Interferons
|2 NLM
|
| 650 |
|
7 |
|a 9008-11-1
|2 NLM
|
| 700 |
1 |
|
|a Vlachiotis, Stelios
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nezos, Adrianos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Andreakos, Evangelos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mavragani, Clio P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tektonidou, Maria G
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 209(2019) vom: 01. Dez., Seite 108265
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:209
|g year:2019
|g day:01
|g month:12
|g pages:108265
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.108265
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 209
|j 2019
|b 01
|c 12
|h 108265
|